Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 12 citing articles:

Temozolomide chemotherapy for patients with newly diagnosed glioblastoma in the CENTRIC EORTC 26071-22072 and CORE trials: does time of administration matter?
Marjolein Geurts, Luzia Berchtold, Franz Koenig, et al.
Neuro-Oncology Practice (2025) Vol. 12, Iss. 2, pp. 291-300
Closed Access
Treatment practices and survival outcomes for IDH-wildtype glioblastoma patients according to MGMT promoter methylation status: insights from the U.S. National Cancer Database
John Pham, David J. Coté, Keiko M. Kang, et al.
Journal of Neuro-Oncology (2025)
Open Access
Canadian Expert Consensus Recommendations for the Diagnosis and Management of Glioblastoma: Results of a Delphi Study
Warren Mason, Rebecca A. Harrison, Sarah Lapointe, et al.
Current Oncology (2025) Vol. 32, Iss. 4, pp. 207-207
Open Access
Molecular Testing in Gliomas: What is Necessary in Routine Clinical Practice?
Iyad Alnahhas
Current Oncology Reports (2024)
Open Access | Times Cited: 2
Microglia induce an interferon‐stimulated gene expression profile in glioblastoma and increase glioblastoma resistance to temozolomide
Mia Dahl Sørensen, Rikke Frydendahl Sick Olsen, Mark Burton, et al.
Neuropathology and Applied Neurobiology (2024) Vol. 50, Iss. 6
Open Access | Times Cited: 1
Temozolomide Use in Elderly Patients with MGMT Promoter Unmethylated Glioblastoma: Is It Finally Time to Dismount a Dead Horse?
Uğur Sener, Erik P. Sulman, Jann N. Sarkaria
Neuro-Oncology (2024) Vol. 26, Iss. 10, pp. 1876-1877
Closed Access
Pathological diagnosis of central nervous system tumours in adults: what’s new?
Evert-Jan Kooi, Lukas Marcelis, Pieter Wesseling
Pathology (2024)
Closed Access
Prognostic Factors for Overall Survival in Elderly Patients with Glioblastoma: Analysis of the Pooled NOA-08 and Nordic trials with the CCTG-EORTC (CE.6) Trial
Annika Malmström, Felix Boakye Oppong, Chris O’Callaghan, et al.
Neuro-Oncology Advances (2024) Vol. 6, Iss. 1
Open Access
Comment on “Amino-acid PET as a prognostic tool after post-stupp protocol temozolomide therapy in high-grade glioma patients”
Trent Kite, Matthew J. Shepard
Journal of Neuro-Oncology (2024) Vol. 170, Iss. 2, pp. 463-464
Closed Access
Well-intentioned is not always beneficial: why we should question prescription habits
Christine Marosi
Neuro-Oncology Practice (2024) Vol. 11, Iss. 6, pp. 677-678
Closed Access
Clinical trial design for novel targeted agents in neuro-oncology
Mary Jane Lim-Fat, Katrina Roberto, P. Y. Wen
Journal of Neuro-Oncology (2024)
Closed Access
Precision radiotherapy with molecular-profiling of CNS tumours
Deepak Dinakaran, Daniel Moore-Palhares, Fan Yang, et al.
Journal of Neuro-Oncology (2024)
Closed Access
Page 1

Scroll to top